Amyotrophic Lateral Sclerosis Drugs Market Report

Global Amyotrophic Lateral Sclerosis Drugs Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Feb 23, 2022
  • PAGES：181
  • REPORT CODE：GMM764213
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Amyotrophic Lateral Sclerosis Drugs market report explains the definition, types, applications, major countries, and major players of the Amyotrophic Lateral Sclerosis Drugs market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Covis Pharma

    • CSPC Pharmaceutical

    • Mitsubishi Tanabe Pharma

    • Mylan

    • Apotex

    • Lunan Pharma

    • Ascend Laboratories

    • Sun Pharma

    • Sanofi

    • EISAI

    • Glemark Generics

    By Type:

    • Riluzole

    • Edaravone (Radicava)

    • CoQ10

    • Butylphthalide

    • Others

    By End-User:

    • Hospital Pharmacies

    • Retail Pharmacies

    • Online Pharmacies

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Amyotrophic Lateral Sclerosis Drugs Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Amyotrophic Lateral Sclerosis Drugs Outlook to 2028- Original Forecasts

    • 2.2 Amyotrophic Lateral Sclerosis Drugs Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Amyotrophic Lateral Sclerosis Drugs Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Amyotrophic Lateral Sclerosis Drugs Market- Recent Developments

    • 6.1 Amyotrophic Lateral Sclerosis Drugs Market News and Developments

    • 6.2 Amyotrophic Lateral Sclerosis Drugs Market Deals Landscape

    7 Amyotrophic Lateral Sclerosis Drugs Raw Materials and Cost Structure Analysis

    • 7.1 Amyotrophic Lateral Sclerosis Drugs Key Raw Materials

    • 7.2 Amyotrophic Lateral Sclerosis Drugs Price Trend of Key Raw Materials

    • 7.3 Amyotrophic Lateral Sclerosis Drugs Key Suppliers of Raw Materials

    • 7.4 Amyotrophic Lateral Sclerosis Drugs Market Concentration Rate of Raw Materials

    • 7.5 Amyotrophic Lateral Sclerosis Drugs Cost Structure Analysis

      • 7.5.1 Amyotrophic Lateral Sclerosis Drugs Raw Materials Analysis

      • 7.5.2 Amyotrophic Lateral Sclerosis Drugs Labor Cost Analysis

      • 7.5.3 Amyotrophic Lateral Sclerosis Drugs Manufacturing Expenses Analysis

    8 Global Amyotrophic Lateral Sclerosis Drugs Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Amyotrophic Lateral Sclerosis Drugs Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Amyotrophic Lateral Sclerosis Drugs Export by Region (Top 10 Countries) (2017-2028)

    9 Global Amyotrophic Lateral Sclerosis Drugs Market Outlook by Types and Applications to 2022

    • 9.1 Global Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Riluzole Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Edaravone (Radicava) Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global CoQ10 Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Butylphthalide Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global $Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Retail Pharmacies Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Online Pharmacies Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Amyotrophic Lateral Sclerosis Drugs Market Analysis and Outlook till 2022

    • 10.1 Global Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.2.2 Canada Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.2.3 Mexico Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.3.2 UK Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.3.3 Spain Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.3.4 Belgium Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.3.5 France Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.3.6 Italy Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.3.7 Denmark Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.3.8 Finland Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.3.9 Norway Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.3.10 Sweden Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.3.11 Poland Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.3.12 Russia Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.3.13 Turkey Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.4.2 Japan Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.4.3 India Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.4.4 South Korea Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.4.5 Pakistan Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.4.6 Bangladesh Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.4.7 Indonesia Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.4.8 Thailand Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.4.9 Singapore Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.4.10 Malaysia Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.4.11 Philippines Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.4.12 Vietnam Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.5.2 Colombia Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.5.3 Chile Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.5.4 Argentina Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.5.5 Venezuela Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.5.6 Peru Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.5.7 Puerto Rico Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.5.8 Ecuador Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.6.2 Kuwait Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.6.3 Oman Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.6.4 Qatar Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.7.2 South Africa Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.7.3 Egypt Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.7.4 Algeria Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

      • 10.8.2 New Zealand Amyotrophic Lateral Sclerosis Drugs Consumption (2017-2022)

    11 Global Amyotrophic Lateral Sclerosis Drugs Competitive Analysis

    • 11.1 Covis Pharma

      • 11.1.1 Covis Pharma Company Details

      • 11.1.2 Covis Pharma Amyotrophic Lateral Sclerosis Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Covis Pharma Amyotrophic Lateral Sclerosis Drugs Main Business and Markets Served

      • 11.1.4 Covis Pharma Amyotrophic Lateral Sclerosis Drugs Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 CSPC Pharmaceutical

      • 11.2.1 CSPC Pharmaceutical Company Details

      • 11.2.2 CSPC Pharmaceutical Amyotrophic Lateral Sclerosis Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 CSPC Pharmaceutical Amyotrophic Lateral Sclerosis Drugs Main Business and Markets Served

      • 11.2.4 CSPC Pharmaceutical Amyotrophic Lateral Sclerosis Drugs Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Mitsubishi Tanabe Pharma

      • 11.3.1 Mitsubishi Tanabe Pharma Company Details

      • 11.3.2 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis Drugs Main Business and Markets Served

      • 11.3.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis Drugs Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Mylan

      • 11.4.1 Mylan Company Details

      • 11.4.2 Mylan Amyotrophic Lateral Sclerosis Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Mylan Amyotrophic Lateral Sclerosis Drugs Main Business and Markets Served

      • 11.4.4 Mylan Amyotrophic Lateral Sclerosis Drugs Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Apotex

      • 11.5.1 Apotex Company Details

      • 11.5.2 Apotex Amyotrophic Lateral Sclerosis Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Apotex Amyotrophic Lateral Sclerosis Drugs Main Business and Markets Served

      • 11.5.4 Apotex Amyotrophic Lateral Sclerosis Drugs Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Lunan Pharma

      • 11.6.1 Lunan Pharma Company Details

      • 11.6.2 Lunan Pharma Amyotrophic Lateral Sclerosis Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Lunan Pharma Amyotrophic Lateral Sclerosis Drugs Main Business and Markets Served

      • 11.6.4 Lunan Pharma Amyotrophic Lateral Sclerosis Drugs Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Ascend Laboratories

      • 11.7.1 Ascend Laboratories Company Details

      • 11.7.2 Ascend Laboratories Amyotrophic Lateral Sclerosis Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Ascend Laboratories Amyotrophic Lateral Sclerosis Drugs Main Business and Markets Served

      • 11.7.4 Ascend Laboratories Amyotrophic Lateral Sclerosis Drugs Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Sun Pharma

      • 11.8.1 Sun Pharma Company Details

      • 11.8.2 Sun Pharma Amyotrophic Lateral Sclerosis Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Sun Pharma Amyotrophic Lateral Sclerosis Drugs Main Business and Markets Served

      • 11.8.4 Sun Pharma Amyotrophic Lateral Sclerosis Drugs Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 Sanofi

      • 11.9.1 Sanofi Company Details

      • 11.9.2 Sanofi Amyotrophic Lateral Sclerosis Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 Sanofi Amyotrophic Lateral Sclerosis Drugs Main Business and Markets Served

      • 11.9.4 Sanofi Amyotrophic Lateral Sclerosis Drugs Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    • 11.10 EISAI

      • 11.10.1 EISAI Company Details

      • 11.10.2 EISAI Amyotrophic Lateral Sclerosis Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.10.3 EISAI Amyotrophic Lateral Sclerosis Drugs Main Business and Markets Served

      • 11.10.4 EISAI Amyotrophic Lateral Sclerosis Drugs Product Portfolio

      • 11.10.5 Recent Research and Development Strategies

    • 11.11 Glemark Generics

      • 11.11.1 Glemark Generics Company Details

      • 11.11.2 Glemark Generics Amyotrophic Lateral Sclerosis Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.11.3 Glemark Generics Amyotrophic Lateral Sclerosis Drugs Main Business and Markets Served

      • 11.11.4 Glemark Generics Amyotrophic Lateral Sclerosis Drugs Product Portfolio

      • 11.11.5 Recent Research and Development Strategies

    12 Global Amyotrophic Lateral Sclerosis Drugs Market Outlook by Types and Applications to 2028

    • 12.1 Global Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Riluzole Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Edaravone (Radicava) Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global CoQ10 Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global Butylphthalide Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.5 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Retail Pharmacies Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Online Pharmacies Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Amyotrophic Lateral Sclerosis Drugs Market Analysis and Outlook to 2028

    • 13.1 Global Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.2.2 Canada Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.3.2 UK Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.3.3 Spain Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.3.5 France Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.3.6 Italy Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.3.8 Finland Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.3.9 Norway Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.3.11 Poland Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.3.12 Russia Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.4.2 Japan Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.4.3 India Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.5.3 Chile Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.5.6 Peru Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.6.3 Oman Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Amyotrophic Lateral Sclerosis Drugs Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Amyotrophic Lateral Sclerosis Drugs

    • Figure of Amyotrophic Lateral Sclerosis Drugs Picture

    • Table Global Amyotrophic Lateral Sclerosis Drugs Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Amyotrophic Lateral Sclerosis Drugs Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Riluzole Consumption and Growth Rate (2017-2022)

    • Figure Global Edaravone (Radicava) Consumption and Growth Rate (2017-2022)

    • Figure Global CoQ10 Consumption and Growth Rate (2017-2022)

    • Figure Global Butylphthalide Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)

    • Figure Global Retail Pharmacies Consumption and Growth Rate (2017-2022)

    • Figure Global Online Pharmacies Consumption and Growth Rate (2017-2022)

    • Figure Global Amyotrophic Lateral Sclerosis Drugs Consumption by Country (2017-2022)

    • Table North America Amyotrophic Lateral Sclerosis Drugs Consumption by Country (2017-2022)

    • Figure United States Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Canada Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Mexico Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Table Europe Amyotrophic Lateral Sclerosis Drugs Consumption by Country (2017-2022)

    • Figure Germany Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure UK Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Spain Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Belgium Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure France Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Italy Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Denmark Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Finland Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Norway Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Sweden Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Poland Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Russia Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Turkey Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Table APAC Amyotrophic Lateral Sclerosis Drugs Consumption by Country (2017-2022)

    • Figure China Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Japan Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure India Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure South Korea Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Thailand Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Singapore Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Philippines Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Table South America Amyotrophic Lateral Sclerosis Drugs Consumption by Country (2017-2022)

    • Figure Brazil Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Colombia Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Chile Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Argentina Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Peru Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Table GCC Amyotrophic Lateral Sclerosis Drugs Consumption by Country (2017-2022)

    • Figure Bahrain Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Oman Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Qatar Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Table Africa Amyotrophic Lateral Sclerosis Drugs Consumption by Country (2017-2022)

    • Figure Nigeria Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure South Africa Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Egypt Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure Algeria Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Table Oceania Amyotrophic Lateral Sclerosis Drugs Consumption by Country (2017-2022)

    • Figure Australia Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Amyotrophic Lateral Sclerosis Drugs Consumption and Growth Rate (2017-2022)

    • Table Covis Pharma Company Details

    • Table Covis Pharma Amyotrophic Lateral Sclerosis Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Covis Pharma Amyotrophic Lateral Sclerosis Drugs Main Business and Markets Served

    • Table Covis Pharma Amyotrophic Lateral Sclerosis Drugs Product Portfolio

    • Table CSPC Pharmaceutical Company Details

    • Table CSPC Pharmaceutical Amyotrophic Lateral Sclerosis Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table CSPC Pharmaceutical Amyotrophic Lateral Sclerosis Drugs Main Business and Markets Served

    • Table CSPC Pharmaceutical Amyotrophic Lateral Sclerosis Drugs Product Portfolio

    • Table Mitsubishi Tanabe Pharma Company Details

    • Table Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis Drugs Main Business and Markets Served

    • Table Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis Drugs Product Portfolio

    • Table Mylan Company Details

    • Table Mylan Amyotrophic Lateral Sclerosis Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mylan Amyotrophic Lateral Sclerosis Drugs Main Business and Markets Served

    • Table Mylan Amyotrophic Lateral Sclerosis Drugs Product Portfolio

    • Table Apotex Company Details

    • Table Apotex Amyotrophic Lateral Sclerosis Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Apotex Amyotrophic Lateral Sclerosis Drugs Main Business and Markets Served

    • Table Apotex Amyotrophic Lateral Sclerosis Drugs Product Portfolio

    • Table Lunan Pharma Company Details

    • Table Lunan Pharma Amyotrophic Lateral Sclerosis Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Lunan Pharma Amyotrophic Lateral Sclerosis Drugs Main Business and Markets Served

    • Table Lunan Pharma Amyotrophic Lateral Sclerosis Drugs Product Portfolio

    • Table Ascend Laboratories Company Details

    • Table Ascend Laboratories Amyotrophic Lateral Sclerosis Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Ascend Laboratories Amyotrophic Lateral Sclerosis Drugs Main Business and Markets Served

    • Table Ascend Laboratories Amyotrophic Lateral Sclerosis Drugs Product Portfolio

    • Table Sun Pharma Company Details

    • Table Sun Pharma Amyotrophic Lateral Sclerosis Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sun Pharma Amyotrophic Lateral Sclerosis Drugs Main Business and Markets Served

    • Table Sun Pharma Amyotrophic Lateral Sclerosis Drugs Product Portfolio

    • Table Sanofi Company Details

    • Table Sanofi Amyotrophic Lateral Sclerosis Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi Amyotrophic Lateral Sclerosis Drugs Main Business and Markets Served

    • Table Sanofi Amyotrophic Lateral Sclerosis Drugs Product Portfolio

    • Table EISAI Company Details

    • Table EISAI Amyotrophic Lateral Sclerosis Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table EISAI Amyotrophic Lateral Sclerosis Drugs Main Business and Markets Served

    • Table EISAI Amyotrophic Lateral Sclerosis Drugs Product Portfolio

    • Table Glemark Generics Company Details

    • Table Glemark Generics Amyotrophic Lateral Sclerosis Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Glemark Generics Amyotrophic Lateral Sclerosis Drugs Main Business and Markets Served

    • Table Glemark Generics Amyotrophic Lateral Sclerosis Drugs Product Portfolio

    • Figure Global Riluzole Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Edaravone (Radicava) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global CoQ10 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Butylphthalide Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Retail Pharmacies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Online Pharmacies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Amyotrophic Lateral Sclerosis Drugs Consumption Forecast by Country (2017-2022)

    • Table North America Amyotrophic Lateral Sclerosis Drugs Consumption Forecast by Country (2017-2022)

    • Figure United States Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Amyotrophic Lateral Sclerosis Drugs Consumption Forecast by Country (2017-2022)

    • Figure Germany Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Amyotrophic Lateral Sclerosis Drugs Consumption Forecast by Country (2017-2022)

    • Figure China Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Amyotrophic Lateral Sclerosis Drugs Consumption Forecast by Country (2017-2022)

    • Figure Brazil Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Amyotrophic Lateral Sclerosis Drugs Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Amyotrophic Lateral Sclerosis Drugs Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Amyotrophic Lateral Sclerosis Drugs Consumption Forecast by Country (2022-2028)

    • Figure Australia Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Amyotrophic Lateral Sclerosis Drugs Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US